Combination PANVAC, Docetaxel May Provide Benefit in Breast Cancer

Share this content:
Combination of PANVAC and docetaxel in metastatic breast cancer may provide clinical benefit.
Combination of PANVAC and docetaxel in metastatic breast cancer may provide clinical benefit.

Results from an open-label phase 2 randomized clinical trial suggested that the combination of PANVAC and docetaxel in metastatic breast cancer may provide clinical benefit, according to an article published online ahead of print in JAMA Oncology.

Previous phase 1 and 2 trials of PANVAC, a poxviral-based cancer vaccine, have suggested clinical efficacy in patients with different tumor types such as breast, ovarian, and colorectal and have shown evidence of immunologic activity. Preclinical data have demonstrated that docetaxel can modify tumor phenotype, making tumors more amenable to T-cell mediated killing.

Researchers investigated the combination of docetaxel and PANVAC to evaluate if the combination improved clinical outcomes in patients with metastatic breast cancer compared with docetaxel treatment alone.

A total of 48 patients with metastatic breast cancer of all subtypes were enrolled, without limitation on other lines of previous therapy. Twenty-five were randomized to the combination treatment arm (A) and 23 to the docetaxel-alone arm (B).

RELATED: Obesity May Promote Breast Cancer by Changing Tissue Structure

In regard to safety, analysis of both arms showed very little difference between the groups. Patients in Arm A had statistically significant increase in the frequency of grades 1 and 2 edema (P=0.02), which was likely associated with a greater median number of docetaxel cycles and injection-site reactions (P<0.001).

Final data analysis showed an advantage for arm A in median progression-free survival (7.9 months versus 3.9 months; HR, 0.65; 95% CI, 0.34, 1.14; P=0.09). The study provides both a rationale and statistical assumptions for a larger definitive randomized study.

Reference

  1. Heery CR, Ibrahim NK, Arlen PM, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 2015. [epub ahead of print]. doi: 10.1001/jamaoncol.2015.2736.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters